Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma

The prognosis for patients with MM has improved substantially over the past 2 decades with the introduction of therapeutics that have improved patient quality of life and prolonged overall survival (OS). With the exception of CAR T cells and BiTEs, these antimyeloma drugs have been combined in doublet, triplet, or quadruplet regimens and have been delivered, when appropriate, antecedent to autologous stem cell transplantation (ASCT).2 As Gahvari and Callander point out, there is currently no consensus treatment for patients with RRMM. [...]historically, the likelihood of a response to the next line of therapy is low, regardless of the agent. [...]the broad administration of cellular therapies and the expansion of precision medicine approaches to treat MM will impact patient distribution to community oncologists, academic health centers, and specialized clinical centers that are designed to streamline CAR T-cell production, distribution, and administration.